Drug research firm Covance (CVD -2.4%) trades lower, erasing an early 4% gain on solid Q3...

|About: Covance Inc. (CVD)|By:, SA News Editor

Drug research firm Covance (CVD -2.4%) trades lower, erasing an early 4% gain on solid Q3 results as revenue grew in both segments. Operating margin swung to 9.4% from negative 16.1%. The company also narrows its full-year earnings estimate from between $2.60 - $2.80 to $2.70.